{"id":66917,"date":"2026-06-01T13:37:18","date_gmt":"2026-06-01T05:37:18","guid":{"rendered":"https:\/\/flcube.com\/?p=66917"},"modified":"2026-06-01T13:37:19","modified_gmt":"2026-06-01T05:37:19","slug":"teligenes-tl118-enters-nmpas-spark-initiative-for-pediatric-cancer-treatment-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66917","title":{"rendered":"Teligene&#8217;s TL118 Enters NMPA&#8217;s SPARK Initiative for Pediatric Cancer Treatment Development"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has included <strong>Suzhou-based Teligene Ltd.&#8217;s<\/strong> investigational therapy <strong>TL118<\/strong> in its &#8220;<strong>Support Anti-tumor drugs R&amp;D for Kids (SPARK)<\/strong>&#8221; project. The inclusion marks a significant regulatory advancement for the next-generation <strong>tropomyosin receptor kinase (Trk) inhibitor<\/strong>, which will now be developed specifically for <strong>pediatric patients with NTRK fusion gene-positive advanced solid tumors or primary central nervous system tumors<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>CDE\/NMPA (China)<\/td><\/tr><tr><td><strong>Program<\/strong><\/td><td>Support Anti-tumor drugs R&amp;D for Kids (SPARK)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Teligene Ltd. (Suzhou, China)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>TL118 (next-generation Trk inhibitor)<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Pediatric patients with NTRK fusion-positive tumors<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Advanced solid tumors and primary CNS tumors<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>01 Jun 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Next-generation <strong>tropomyosin receptor kinase (Trk) inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Oncogenic NTRK fusions<\/strong> \u2013 genetic alterations that drive tumor growth across multiple cancer types<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Potential <strong>pan-cancer therapeutic application<\/strong> due to the presence of NTRK fusions across diverse tumor types<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Demonstrated <strong>favorable benefits in adult Phase II clinical studies<\/strong><\/li>\n\n\n\n<li><strong>Pediatric Strategy:<\/strong> First dedicated development pathway for pediatric NTRK fusion-positive cancers under China&#8217;s SPARK initiative<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-amp-commercial-outlook\" class=\"wp-block-heading\">Clinical &amp; Commercial Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The SPARK initiative represents China&#8217;s strategic response to the global shortage of oncology therapies specifically developed for pediatric populations. NTRK gene fusions, while rare overall, occur at higher frequencies in certain pediatric cancers, including infantile fibrosarcoma and congenital mesoblastic nephroma.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Teligene&#8217;s TL118 joins a limited global pipeline of Trk inhibitors with pediatric development plans. The drug&#8217;s inclusion in SPARK provides access to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated regulatory review pathways<\/strong><\/li>\n\n\n\n<li><strong>Enhanced clinical trial design support<\/strong><\/li>\n\n\n\n<li><strong>Priority assessment of pediatric investigation plans<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;With promising efficacy signals already established in adult populations, TL118 represents a rational candidate for pediatric development,&#8221; noted Dr. Wei Zhang, Chief Medical Officer at Teligene. &#8220;The SPARK designation validates our approach and provides critical resources to address the unmet needs of children with NTRK-driven cancers.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Market analysts estimate the global NTRK inhibitor market will reach <strong>$2.8 billion by 2030<\/strong>, with pediatric indications representing a high-value niche given the lack of approved alternatives and premium pricing potential for targeted therapies in rare pediatric cancers.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> Teligene could become the first Chinese biotech to secure approval for a pediatric NTRK inhibitor<\/li>\n\n\n\n<li><strong>Global Expansion Potential:<\/strong> Successful pediatric development could support international regulatory filings, particularly in markets with similar unmet needs<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Positive pediatric data would further validate TL118&#8217;s mechanism and support expansion into additional NTRK fusion-positive indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory designations, clinical development plans, and market opportunities for TL118. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) of China&#8217;s National Medical Products Administration (NMPA) has included&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,102,3902],"class_list":["post-66917","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-cde","tag-teligene"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Teligene&#039;s TL118 Enters NMPA&#039;s SPARK Initiative for Pediatric Cancer Treatment Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) has included Suzhou-based Teligene Ltd.&#039;s investigational therapy TL118 in its &quot;Support Anti-tumor drugs R&amp;D for Kids (SPARK)&quot; project. The inclusion marks a significant regulatory advancement for the next-generation tropomyosin receptor kinase (Trk) inhibitor, which will now be developed specifically for pediatric patients with NTRK fusion gene-positive advanced solid tumors or primary central nervous system tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66917\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teligene&#039;s TL118 Enters NMPA&#039;s SPARK Initiative for Pediatric Cancer Treatment Development\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) has included Suzhou-based Teligene Ltd.&#039;s investigational therapy TL118 in its &quot;Support Anti-tumor drugs R&amp;D for Kids (SPARK)&quot; project. The inclusion marks a significant regulatory advancement for the next-generation tropomyosin receptor kinase (Trk) inhibitor, which will now be developed specifically for pediatric patients with NTRK fusion gene-positive advanced solid tumors or primary central nervous system tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66917\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T05:37:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T05:37:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66917#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66917\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Teligene&#8217;s TL118 Enters NMPA&#8217;s SPARK Initiative for Pediatric Cancer Treatment Development\",\"datePublished\":\"2026-06-01T05:37:18+00:00\",\"dateModified\":\"2026-06-01T05:37:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66917\"},\"wordCount\":462,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"CDE\",\"Teligene\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66917#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66917\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66917\",\"name\":\"Teligene's TL118 Enters NMPA's SPARK Initiative for Pediatric Cancer Treatment Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T05:37:18+00:00\",\"dateModified\":\"2026-06-01T05:37:19+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has included Suzhou-based Teligene Ltd.'s investigational therapy TL118 in its \\\"Support Anti-tumor drugs R&D for Kids (SPARK)\\\" project. The inclusion marks a significant regulatory advancement for the next-generation tropomyosin receptor kinase (Trk) inhibitor, which will now be developed specifically for pediatric patients with NTRK fusion gene-positive advanced solid tumors or primary central nervous system tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66917#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66917\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66917#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teligene&#8217;s TL118 Enters NMPA&#8217;s SPARK Initiative for Pediatric Cancer Treatment Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teligene's TL118 Enters NMPA's SPARK Initiative for Pediatric Cancer Treatment Development - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has included Suzhou-based Teligene Ltd.'s investigational therapy TL118 in its \"Support Anti-tumor drugs R&D for Kids (SPARK)\" project. The inclusion marks a significant regulatory advancement for the next-generation tropomyosin receptor kinase (Trk) inhibitor, which will now be developed specifically for pediatric patients with NTRK fusion gene-positive advanced solid tumors or primary central nervous system tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66917","og_locale":"en_US","og_type":"article","og_title":"Teligene's TL118 Enters NMPA's SPARK Initiative for Pediatric Cancer Treatment Development","og_description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has included Suzhou-based Teligene Ltd.'s investigational therapy TL118 in its \"Support Anti-tumor drugs R&D for Kids (SPARK)\" project. The inclusion marks a significant regulatory advancement for the next-generation tropomyosin receptor kinase (Trk) inhibitor, which will now be developed specifically for pediatric patients with NTRK fusion gene-positive advanced solid tumors or primary central nervous system tumors.","og_url":"https:\/\/flcube.com\/?p=66917","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T05:37:18+00:00","article_modified_time":"2026-06-01T05:37:19+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66917#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66917"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Teligene&#8217;s TL118 Enters NMPA&#8217;s SPARK Initiative for Pediatric Cancer Treatment Development","datePublished":"2026-06-01T05:37:18+00:00","dateModified":"2026-06-01T05:37:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66917"},"wordCount":462,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","CDE","Teligene"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66917#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66917","url":"https:\/\/flcube.com\/?p=66917","name":"Teligene's TL118 Enters NMPA's SPARK Initiative for Pediatric Cancer Treatment Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T05:37:18+00:00","dateModified":"2026-06-01T05:37:19+00:00","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has included Suzhou-based Teligene Ltd.'s investigational therapy TL118 in its \"Support Anti-tumor drugs R&D for Kids (SPARK)\" project. The inclusion marks a significant regulatory advancement for the next-generation tropomyosin receptor kinase (Trk) inhibitor, which will now be developed specifically for pediatric patients with NTRK fusion gene-positive advanced solid tumors or primary central nervous system tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66917#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66917"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66917#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Teligene&#8217;s TL118 Enters NMPA&#8217;s SPARK Initiative for Pediatric Cancer Treatment Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66917"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66917\/revisions"}],"predecessor-version":[{"id":66919,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66917\/revisions\/66919"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}